Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia

被引:7
|
作者
Heffelfinger, James D. [1 ]
Voetsch, Andrew C. [1 ]
Nakamura, Glenn V. [1 ]
Sullivan, Patrick S. [2 ]
McNaghten, A. D. [1 ]
Huang, Laurence [3 ,4 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[3] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Pulmonary & Critical Care Med, San Francisco, CA 94143 USA
来源
PLOS ONE | 2009年 / 4卷 / 03期
基金
美国国家卫生研究院;
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CARINII PNEUMONIA; UNITED-STATES; DRUG-USE; ADHERENCE; PATIENT; EPIDEMIOLOGY; BIAS; AIDS;
D O I
10.1371/journal.pone.0005002
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis. Methodology/Principal Findings: We used 2000-2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons >= 18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question "In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?'' We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1-2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0-2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3-4.1) in the past year; their mental health was "not good'' for >= 1 day during the past month (aOR = 1.6, 95% CI = 1.2-2.2); their most recent CD4 count was,200 cells/mu L (aOR = 1.6, 95% CI = 1.1-2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7-13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1-30.4), compared with always, as prescribed. Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis, particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce the occurrence of PCP.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] IS DAPSONE SAFE FOR PNEUMOCYSTIS JIROVECII PNEUMONIA PROPHYLAXIS IN KIDNEY AND PANCREAS TRANSPLANT RECIPIENTS?
    Simpson, Jaqueline
    Truax, Crystal
    Cairns, Taylor
    Zukauckas, Kelsea
    Raghavan, Divya
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [42] Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone
    Vas, A.
    Laws, P.
    Marsland, A. M.
    McQuillan, O.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (09) : 745 - 747
  • [43] Primary prophylaxis against Pneumocystis jirovecii Pneumonia may be effective in preventing severe bacterial pneumonia in HIV-positive patients: findings from a large Italian center
    Dusina, A.
    Ciccullo, A.
    Emiliozzi, A.
    Moschese, D.
    Farinacci, D.
    Belmonti, S.
    Baldin, G.
    Di Giambenedetto, S.
    HIV MEDICINE, 2019, 20 : 216 - 216
  • [44] Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review
    Sierra, Caroline M.
    Daiya, Krishna C.
    PHARMACOTHERAPY, 2022, 42 (11): : 858 - 867
  • [45] IMPROVING ADHERENCE TO PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP) PROPHYLAXIS IN LUNG TRANSPLANT RECIPIENTS
    Djavadkhani, Y.
    Harkess, M.
    Carlos, L.
    Glanville, A. R.
    IMMUNOLOGY AND CELL BIOLOGY, 2013, 91 (08): : A26 - A26
  • [46] PNEUMOCYSTIS JIROVECII PROPHYLAXIS IN PATIENTS ON RITUXIMAB
    Warrier, Kishore
    Salvesani, Catherine
    Deepak, Samundeeswari
    RHEUMATOLOGY, 2019, 58
  • [47] Pneumocystis jirovecii: The Changing Landscape for Prophylaxis
    Pruett, Timothy L.
    TRANSPLANTATION, 2021, 105 (10) : 2142 - 2143
  • [48] Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?
    Barbounis, V
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (10): : 490 - 491
  • [49] Pneumocystis jirovecii Exhalation in the Course of Pneumocystis Pneumonia Treatment
    Pougnet, Laurence
    Grall, Anne
    Moal, Marie-Christine
    Pougnet, Richard
    Le Govic, Yohann
    Negri, Steven
    Nevez, Gilles
    Le Gal, Solene
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2018, 39 (05): : 627 - 630
  • [50] Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?
    Vassilios Barbounis
    Nature Clinical Practice Oncology, 2005, 2 : 490 - 491